The trajectory of companies tied to blockbuster drugs like Viagra presents a nuanced investment scenario . While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the expiry in key territories has introduced considerable risk . Investors are now grappling with the effect of rival medications